GPrX wins innovation award for “powerful new hospital dataset”

GPrX and Novartis win “Best Use of Innovation” at the British Healthcare Business Intelligence Association’s 2022 BOBI Awards

GPrX and Novartis representatives accepting award

The British Healthcare Business Intelligence Association's 2022 annual awards were held at a gala dinner in London on Monday 16th May, with local company GPrX winning the trophy for "Best Use of Innovation".

GPrX, a specialist in NHS data analytics, have given Novartis Neurosciences a new way of identifying the hospitals where patients are being treated for Multiple Sclerosis, and which medicines they’re using. Novartis use this information to monitor how widely their new disease modifying therapy Kesimpta is being used across NHS trusts.

Kesimpta is a monthly injection that patients can give themselves. For some patients who would otherwise have to go into hospital for intravenous infusions, this "at home" treatment is more convenient and reduces hospital appointments, taking pressure off the NHS.

The winning entry detailed our new-to-market reporting stream of monthly patient insight data. The judges noted:

  • “Addresses an important data source challenge for pharma companies”
  • “Identified robust / powerful data at hospital level – great value for the business”
  • “A key data source to build company strategy”

Accepting the award for GPrX, Joanna Burnett commented: "I'm delighted that our data has been judged to be a real innovation in information analytics for the life sciences sector, against some strong competition. It's been rewarding to hear the positive impact our work has had for Novartis UK as they try to help people living with multiple sclerosis and their doctors assess newer drug therapies.

We're really proud to be playing a small part in hopefully improving these patients' quality of life and reducing the burden on the NHS."

Looking for something specific?